Oxidative damage and platelet activation as new predictors of mobility disability and mortality in elders

Antioxidants and Redox Signaling

Volumn 8, Issue 3-4, 2006, Pages 609-619

  Cesari, Matteo ^a   Kritchevsky, Stephen B ^b   Leeuwenburgh, Christiaan ^a   Pahor, Marco ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ADENOSINE TRIPHOSPHATASE (CALCIUM); ANTIOXIDANT; CALPAIN; FREE RADICAL;

AGE; AGED; AGING; ATTITUDE TO HEALTH; DIET RESTRICTION; DIET SUPPLEMENTATION; ENZYME ACTIVITY; HUMAN; IMMOBILIZATION; INFLAMMATION; LIPID PEROXIDATION; METABOLIC DISORDER; MORTALITY; MUSCLE ATROPHY; MUSCLE STRENGTH; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PHYSICAL DISABILITY; PREDICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SMOKING CESSATION; THROMBOCYTE ACTIVATION;

AGING; ANIMALS; ANTIOXIDANTS; HUMANS; INFLAMMATION; LIPID PEROXIDATION; MOBILITY LIMITATION; MODELS, BIOLOGICAL; MUSCLES; OXIDATIVE STRESS; OXYGEN; PLATELET ACTIVATION; RISK FACTORS;

EID: 33646686146     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2006.8.609     Document Type: Review

References (120)

1. Anker SD, Ponikowski PP, Clark AL, Leyva F, Rauchhaus M, Kemp M, Teixeira MM, Hellewell PG, Hooper J, Poole-Wilson PA, and Coats AJS. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 20: 683-693, 1999.
2. Arvola P, Wu X, Kahonen M, Makynen H, Riutta A, Mucha I, Solakivi T, Kainulainen H, and Porsti I. Exercise enhances vasorelaxation in experimental obesity associated hypertension. Cardiovasc Res 43: 992-1002, 1999.
3. Avery NG, Kaiser JL, Sharman MJ, Scheett TP, Barnes DM, Gomez AL, Kraemer WJ, and Volek JS. Effects of vitamin E supplementation on recovery from repeated bouts of resistance exercise. J Strength Cond Res 17: 801-809, 2003.
4. Awad JA, Morrow JD, Takahashi K, and Roberts LJ. Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. J Biol Chem. 268: 4161-4169, 1993.
5. Bagi Z, Cseko C, Toth E, and Koller A. Oxidative stress-induced dysregulation of arteriosal wall shear stress and blood pressure in hyperhomocysteinemia is prevented by chronic vitamin C treatment. Am J Physiol Heart Circ Physiol 285: H2277-H2283, 2003.
6. Balakrishnan SD and Anuradha CV. Exercise, depletion of antioxidants and antioxidant manipulation. Cell Biochem Funct 16: 269-275, 1998.
7. Barnett DW and Conlee RK. The effects of a commercial dietary supplement on human performance. Am J Clin Nutr 40: 287-293, 2003.
8. Bartoli M and Richard I. Calpains in muscle wasting. Int J Biochem Cell Biol 37: 2115-2133, 2005.
9. Bhat HK, Calaf G, Hei TK, Loya T, and Vadgama JV. Critical role of oxidative stress in estrogen-induced carcinogenesis. Proc Natl Acad Sci USA 100: 3913-3918, 2003.
10. Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Caan B, and Packer L. Factors associated with oxidative stress in human populations. Am J Epidemiol 156: 274-285, 2002.
11. Carmeli E, Coleman R, and Reznick AZ. The biochemistry of aging muscle. Exp Gerontol 37: 477-489, 2002.
12. Cesari M, Kritchevsky SB, Baumgartner RN, Atkinson HH, Penninx BWJH, Lenchik L, Palla SL, Ambrosius WT, Tracy RP, and Pahor M. Sarcopenia, obesity and inflammation-Results from the TRAIN study. Am J Clin Nutr 82: 428-434, 2005.
13. Cesari M, Kritchevsky SB, Nicklas BJ, Penninx BWJH, Holvoet P, Koh-Banerjee P, Cummings S, Harris TB, Newman AB, and Pahor M. Lipoprotein peroxidation and mobility limitation: results from the Health, Aging and Body Composition Study. Arch Intern Med 165: 2148-2154, 2005.
14. Cesari M, Pahor M, Bartali B, Cherubini A, Penninx BW, Williams GR, Atkinson H, Martin A, Guralnik JM, and Ferrucci L. Antioxidants and physical performance in elderly persons: the Invecchiare in Chianti (InCHIANTI) study. Am J Clin Nutr 79: 289-294, 2004.
15. Cohen HJ, Pieper CF, Harris TB, Rao KM, and Currie MS. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci 52: M201-M208, 1997.
16. Davi G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, Cipollone F, Bon GB, Ciabattoni G, and Patrono C. In vivo formation of 8-epi-prostaglandin F2 alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 17: 3230-3235, 1997.
17. Davi G, Basili S, Vieri M, Cipollone F, Santarone S, Alessandri C, Gazzaniga P, Cordova C, Violi F, and the Chronic Obstructive Bronchitis and Haemostasis Study Group. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 156: 1794-1799, 1997.
18. Davi G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, Basili S, Ciabattoni G, and Patrono C. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus-Role of interleukin-6 and disease duration. Circulation 107: 3199-3203, 2003.
19. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, and Patrono C. In vivo formation of 8-iso-prostaglandin F2 alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99: 224-229, 1999.
20. Davi G, DiMinno G, Coppola A, Andria G, Cerbone AM, Madonna P, Tufano A, Falco A, Marchesani P, Ciabattoni G, and Patrono C. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 104: 1124-1128, 2001.
21. Davi G, Falco A, and Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipid 128: 149-163, 2004.
22. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, and Patrono C. Platelet activation in obese women: role of inflammation and oxidative stress. JAMA 288: 2008-2014, 2002.
23. Dietrich M, Block G, Hudes M, Morrow JD, Norkus EP, Traber MG, Cross CE, and Packer E. Antioxidant supplementation decreases lipid peroxidation biomarker F2-isoprostane in plasma of smokers. Cancer Epidemiol Biomarkers Prev 11: 7-13, 2002.
24. Dworski R, Roberts LJ, Murray JJ, Morrow JD, Hartert TV. and Sheller JR. Assessment of oxidant stress in allergic asthma by measurement of the major urinary metabolite of F2-isoprostane, 15-F2t-IsoP (8-iso-PGF2alpha). Clin Exp Allergy 31:387-390, 2001.
25. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650-1655, 2002.
26. Facchini FS, Hua NW, Reaven GM, and Stoohs RA. Hyperinsulinemia: the missing link among oxidative stress and age-related diseases? Free Radic Biol Med 29: 1302-1306, 2000.
27. Fai Poon H, Calabrese V, Scapagnini G, and Butterfield DA. Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J Gerontol A Biol Sci Med Sci 59A: 478-493, 2004.
28. Fano G, Mecocci P, Vecchiet J, Belia S, Fulle S, Polidori MC, Felzani G, Senin U, Vecchiet L, and Beal MF. Age and sex influence on oxidative damage and functional status in human skeletal muscle. J Muscle Res Cell Motil 22: 345-351, 2001.
29. Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ, Penninx BWJH, Pahor M, Wallace RB, and Havlik RJ. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 47: 639-646, 1999.
30. Fiebich BL, Hull M, Lieb K, Gyufko K, Berger M, and Bauer J. Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells. J Neurochem 68: 704-709, 1997.
31. Frei B, England L, and Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA 86: 6377-6381, 1989.
32. Frei B, Forte TM, Ames BN, and Cross CE. Gas phase oxidants of cigarrette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Biochem 277: 133-138, 1991.
33. Fried LP and Guralnik JM. Disability in older adults: evidence regarding significance, etiology, and risk. J Am Geriatr Soc 45: 92-100, 1997.
34. Fulle S, Protasi F, Di Tano G, Pietrangelo T, Beltramin A, Boncompagni S, Vecchiet L, and Fano G. The contribution of reactive oxygen species to sarcopenia and muscle ageing. Exp Gerontol 39: 17-24, 2004.
35. Gale CR, Ashurst HE, Powers HJ, and Martyn CN. Antioxidant vitamin status and carotid atherosclerosis in the elderly. Am J Clin Nutr 74: 402-408, 2001.
36. Gaziano JM, Manson JE, Branch LG, Colditz GA, Willett WC, and Buring JE. A prospective study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. Ann Epidemiol 5: 255-260, 1995.
37. Goll DE, Thompson VF, Li H, Wei W, and Cong J. The calpain system. Physiol Rev 83: 731-801, 2003.
38. Greco A, Minghetti L, and Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem Res 25: 1357-1364, 2000.
39. Greco A, Minghetti L, Sette G, Fieschi C, and Levi G. Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 53: 1876-1879, 1999.
40. Grune T, Merker K, Sandig G, and Davies KJ. Selective degradation of oxidatively modified protein substrates by the proteasome. Biochem Biophys Res Comm 305: 709-718, 2003.
41. Halliwell B, and Gutteridge JMC. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 186: 1-85, 1990.
42. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, and Blumberg JB. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 59: 1960-1966, 2001.
43. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 2: 298-300, 1957.
44. Harman D. The free radical theory of aging. Antioxid Redox Signal 5: 557-561, 2003.
45. Haslett P, Hempstead M, Seidman C, Diakun J, Vasquez D, Freedman VH, and Kaplan G. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 13: 1047-1054, 1997.
46. Hauer K, Hildebrandt W, Sehl Y, Edler L, Oster P, and Dröge W. Improvement in muscular performance and decrease in tumor necrosis factor level in old age after antioxidant treatment. J Mol Med 81: 118-125, 2003.
47. Helmersson J, and Basu S. F2-isoprostane excretion rate and diurnal variation in human urine. Prostaglandins Leukot Essent Fatty Acids 61: 203-205, 1999.
48. Hishinuma T, Tsukamoto H, Suzuki K, and Mizugaki M. Relationship between thromboxane/prostaclicin ratio and diabetic vascular complications. Prostaglandins Leukot Essent Fatty Acids 53: 191-196, 2001.
49. Hoshino E, Pichard C, Greenwood CE, Huo GC, Cameron RG, Kurian R, Kearns JP, Allard JP, and Jeejeebhoy KN. Body composition and metabolic rate in rat during a continuous infusion of cachectin. Am J Physiol 260: E27-E36, 1991.
50. Hu P, Reuben DB, Crimmins EM, Harris TB, Huang MH, and Seeman TE. The effects of serum beta-carotene concentration and burden of inflammation on all-cause mortality risk in high-functioning, older persons: MacArthur Studies of Successful Aging. J Gemntol A Biol Sci Med Sci 59A: 849-854, 2004.
51. Ikonomidis I, Lekakis J, Vamvakou G, Andreotti F, and Nihoyannopoulos P. Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. Am Heart J 149: 832-839, 2005.
52. Janssen LJ. Isoprostanes: an overview and putative roles in pulmonary patliophysiology. Am J Physiol Lung Cell Mol Physiol 280: L1067-L1082, 2001.
53. Keaney JF, Jr., Larson MG, Vasan RS, Wilson PWF, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, and Benjamin EJ. Obesity and systemic oxidative stress-Clinical correlates of oxidative stress in The Framingham Study. Arteriosder Thromb Vasc Biol 23: 434-439, 2003.
54. Kostikas K, Papatheodorou G, Psathakis K, Panagou P, and Loukides S. Oxidative stress in expired breath condensate of patients with COPD. Chest 124: 1373-1380, 2003.
55. Kozawa O, Suzuki A, Tokuda H, and Uematsu T. Prostaglandin F2alpha stimulates interleukin-6 synthesis via activation of PKC in osteoblast-like cells. Am J Physiol 272: E208-E211, 1997.
56. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, and Witztum JL, for the Nutrition Committee of the American Heart Association Council on Nutrition Physical Activity and Metabolism. Antioxidant vitamin supplements and cardiovascular disease. Circulation 110: 637-641, 2004.
57. Kurokawa K, Tanaka H, Tanaka S, and Abe S. Circadian characteristics of urinary leukotriene E4 in healthy subjects and nocturnal asthmatic patients. Chest 120: 1822-1828, 2001.
58. Leeuwenburgh C. The role of apoptosis in sarcopenia. J Gerontol A Biol Sci Med Sci 58: 999-1001, 2003.
59. Levi M, van der Poll T, and Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 109: 2698-2704, 2004.
60. Lim PS, Chang YM, Thien LM, Wang NP, Yang CC, Chen TT, and Hsu WM. 8-iso-prostaglandin F2alpha as a useful clinical biomarker of oxidative stress in ESRD patients. Blood Purif 20: 537-542, 2002.
61. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, and Weyrich AS. Activated platelets mediate inflammatory signaling by regulated interleukin 1 beta synthesis. J Cell Biol 154: 485-490, 2001.
62. Liu T, Stern A, Roberts LJ, and Morrow JD. The isoprostanes: novel prostaglandin-like products of the free radical-catalyzed peroxidation of arachidonic acid. J Biomed Sci 6: 226-235, 1999.
63. Longini M, Perrone S, Kenanidis A, Vezzosi P, Marzocchi B, Petraglia F, Centini G, and Buonocore G. Isoprostanes in amniotic fluid: a predictive marker for fetal growth restriction in pregnancy. Free Radic Biol Med 38: 1537-1541, 2005.
64. Longmire AW, Swift LL, Roberts LJ, Awad JA, Burk RF, and Morrow JD. Effect of oxygen tension on the generation of F2-isoprostanes and malondialdehyde in peroxidizing rat liver microsomes. Biochem Pharmacol 47: 1173-1177, 1994.
65. Lynch SM, Morrow JD, Roberts LJ, and Frei B. Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vivo. J Clin Invest 93: 998-1004, 1994.
66. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, and Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 97: 1536-1539, 1998.
67. Maxwell SRJ. Prospects for the use of antioxidant therapies. Drugs 49: 345-361, 1995.
68. McConnell JP, Cheryk LA, Durocher A, Bruno A, Bang NU, Fleck JD, Williams L, Biller J, and Meschia JF. Urinary 11-dehydro-thromboxane B2 and coagulation markers measured within 24 h of human acute ischemic stroke. Neurosci Lett 313: 88-92, 2001.
69. Meade EA, McIntyre TM, Zimmerman GA, and Prescott SM. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 274: 8328-8334, 1999.
70. Mecocci P, Fano G, Fulle S, MacGarvey U, Shinobu L, Polidori MC, Cherubini A, Vecchiet J, Senin U, and Beal MF. Age-dependent increases in oxidative damage to DNA, lipids, and proteins in human skeletal muscle. Free Radic Biol Med 26: 303-308, 1999.
71. Messier SP, Loeser RF, Miller GD, Morgan TM, Rejeski WJ, Sevick MA, Ettinger WH Jr, Pahor M, and Williamson JD. Exercise and diet weight loss in overvveigh and obese older adults with knee osteoarthritis-The Arthritis, Diet, and Activity Promotion Trial. Arthritis Rheum 50: 1501-1510, 2004.
72. Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R, Seta F, Capone ML, Tacconelli S, Palatresi S, Bencini C, Del Vecchio C, Mansueto G, Arosio E, Santonastaso CL, Lechi A, Morganti A, and Patrono C. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 106: 2800-2805, 2002.
73. Minuz P, Patrignani P, Gaino S, Seta F, Capone ML, Tacconelli S, Degan M, Faccini G, Fornasiero A, Talamini G, Tommasoli R, Arosio E, Lechi Santonastaso C, Lechi A, and Patrono C. Determinants of platelet activation in human essential hypertension. Hypertension 43: 64-70, 2004.
74. Montuschi P, Ciabattoni G, Paredi P, Pantelidis P, duBois RM, Kharitonov SA, and Barnes PJ. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 158: 1524-1527, 1998.
75. Moore KP, Darley-Usmar V, Morrow J, and Roberts LJ, II. Formation of F2-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite. Circ Res 77: 335-341, 1995.
76. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, and Nair KS. Sarcopenia. J Lab Clin Med 137: 231-243, 2001.
77. Morrow JD. Qualification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 25: 1-8, 2005.
78. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates J, and Roberts LJ. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med 332: 1198-1203, 1995.
79. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, and Roberts LJ, II. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase free radical-catalized mechanism. Proc Natl Acad Sci USA 87: 9383-9387, 1990.
80. Morrow JD, Minton TA, and Roberts LJ, II. The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a thromboxane/endoperoxide receptor antagonist. Prostaglandins 44: 155-163, 1992.
81. Morrow JD, Oates JA, Roberts LJ, II, Zackert WE, Mitchell TA, Lazarus G, and Guzzo C. Increased formation of thromboxane in vivo in humans with mastocytosis. J Invest Dermatol 113: 93-97, 1999.
82. Morrow JD and Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 36: 1-21, 1997.
83. Murohara T, Ikeda H, Katoh A, Takajo Y, Otsuka Y, Haramaki N, and Imaizumi T. Vitamin E inhibits lysophosphatidylcholine-induced endothelial dysfunction and platelet activation. Antioxid Redox Signal 4: 791-798, 2002.
84. Natarajan R, Lanting L, Gonzales N, and Nadler J. Formation of F2-isoprostanes in vascular smooth muscle cells by elevated glucose and growth factors. Am J Physiol 271: H159-H165, 1996.
85. Newman AB, Arnold AM, Naydeck BL, Fried LP, Burke GL, Enright P, Gottdiener J, Hirsch C, O'Leary D, Tracy R, and Cardiovascular Health Study Research Group. "Successful aging": effect of subclinical cardiovascular disease. Arch Intern Med 163: 2315-2322, 2003.
86. Niki E, Noguchi N, Tsuchihashi H, and Gotoh N. Interaction among vitamin C, vitamin E, and beta-carotene. Am J Clin Nutr 62: 1322S-1326S, 1995.
87. Odding E, Valkenburg HA, Stam HJ, and Hofman A. Determinants of locomotor disability in people aged 55 years and over: the Rotterdam Study. Eur J Epidemiol 17: 1033-1041, 2001.
88. Oostenbrug GS, Mensink RP, Hardeman MR, De Vries T, Brouns F, and Hornstra G. Exercise performance, red blood cell deformability, and lipid peroxidation: effects of fish oil and vitamin E. J Appl Physiol 83: 746-752, 1997.
89. Owen RW. Biomarkers in colorectal cancer. IARC Sci Publ 154: 101-111, 2001.
90. Pansarasa O, Castagna L, Colombi B, Vecchiet J, Felzani G, and Marzatico F. Age and sex differences in human skeletal muscle: role of reactive oxygen species. Free Radic Res 33: 287-293, 2000.
91. Pasceri V, Willerson JT, and Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165-2168, 2000.
92. Patrignani P, Panara MR, Tacconelli S, Seta F, Bucciarelli T, Ciabattoni G, Alessandrini P, Mezzetti A, Santini G, Sciulli MG, Cipollone F, Davi G, Gallina P, Bittolo Bon G, and Patrono C, Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation 102: 539-545, 2000.
93. Patrono C, Ciabattoni G, and Davl G. Thromboxane biosynthesis in cardiovascular diseases. Stroke 21: IV130-IV133, 1990.
94. Patrono C, Falco A, and Davi G. Isoprostane formation and inhibition in atherothrombosis. Curr Opin Pharmacol 5: 198-203, 2005.
95. Phillips T and Leeuwenburgh C. Lifelong aspirin supplementation as a means to extending life span. Rejuvenation Res 7: 243-251, 2004.
96. Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, and Violi F. Vitamin E inhibits collagen-induced platelet activation by blunting hydrogen peroxide. Arterioscler Thromb Vasc Biol 19: 2542-2547, 1999.
97. Powers SK, Kavazis AN, and DeRuisseau KC. Mechanisms of disuses muscle atrophy: role of oxidative stress. Am J Physiol Regul Integr Comp Physiol 288: 337-344, 2005.
98. Pratico D and Fitzgerald GA. Generation of 8-epi-prostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem 271: 8919-8924, 1996.
99. Pratico D, Smyth EM, Violi F, and FitzGerald GA. Local amplification of platelet function by 8-epi prostaglandin F2 alpha is not mediated by thromboxane receptor isoforms. J Biol Chem 271: 14916-14924, 1996.
100. Pratico D, Tangirala RK, Rader DJ, Rokach J, and Fitzgerald GA. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med 4: 1189-1192, 1998.
101. Prince MR, LaMuraglia GM, and MacNichol EF. Increased preferential absorption in human atherosclerotic plaque with oral beta-carotene: implications for laser endarterectomy. Circulation 78: 338-344, 1988.
102. Reilly M, Delanty N, Lawson JA, and Fitzgerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 94: 19-25, 1996.
103. Richter C. Biophysical consequences of lipid peroxidation in membranes. Chem Phys Lipids 44: 175-189. 1987.
104. Sampson MJ, Gopaul N, Davies IR, Hughes DA, and Carrier MJ. Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care 25: 537-541, 2002.
105. Sanchez-Moreno C, Dashe JF, Scott T, Thaler D, Folstein MF, and Martin A. Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxdiative stress markers after stroke. Stroke 35: 163-168, 2004.
106. Sciulli MG, Filabozzi P, Tacconelli S, Padovano R, Ricciotti E, Capone ML, Grana M, Carnevale V, and Patrignani P. Platelet activation in patients with colorectal cancer. Prostaglandins Leukot Essent Fatty Acids 72: 79-83, 2005.
107. Semba RD, Blaum C, Guralnik JM, Moncrief DT, Ricks Mo, and Fried LP. Carotenoid and vitamin E status are associated with indicators of sarcopenia among older women living in the community. Aging Clin Exp Res 15: 482-487, 2003.
108. Shi X, Ding M, Dong Z, Chen F, Ye J, Wang S, Leonard SS, Castranova V, and Vallyathan V. Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage. NF-kappaB activation, and TNF-alpha production. Mol Cell Biochem 199: 93-102, 1999.
109. Siems W, Capuozzo E, Lucano A, Salerno C, and Crifo C. High sensitivity of plasma membrane ion transport AT-Pases from human neutrophils towards 4-hydroxy-2,3-trans-nonenal. Life Sci 73: 2583-2590, 2003.
110. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, and Levin NW. Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 38: 1408-1413, 2001.
111. Squier TC and Bigelow DJ. Protein oxidation and age-dependent alterations in calcium homeostasis. Front Biosci 5: D504-D526, 2000.
112. Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation 95: 1062-1071, 1997.
113. Stuck AE, Walthert JM, Nikolaus T, Bula CJ, Hohmann C, and Beck JC. Risk factors for functional status decline in community-living elderly people: a systematic literature review. Soc Sci Med 48: 445-469, 1999.
114. Upritchard JE, Schuurman CRWC, Wiersma A, Tijburg LBM, Coolen SAJ, Rijken PJ, and Wiseman SA. Spread supplemented with moderate doses of vitamin E and carotenoids reduces lipid peroxidation in healthy, nonsmoking adults. Am J Clin Nutr 78: 985-992, 2003.
115. Volpato S, Blaum C, Resnick H, Ferrucci L, Fried LP, Guralnik JM, and Women's Health and Aging Study. Comorbidities and impairments explaining the association between diabetes and lower extremity disability: The Women's Health and Aging Study. Diabetes Care 25: 678-683, 2002.
116. Volpato S, Gwalnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, and Harris TB. Cardiovascular disease, interleukin-6, and risk of mortality in older women-The Women's Health and Aging Study. Circulation 103: 947-953, 2001.
117. Ward WF, Qi W, Van Remmen H, Zackert WE, Roberts LJ, II, and Richardson A. Effects of age and caloric restriction on lipid peroxidation: measurement of oxidative stress by F2-isoprostane levels. J Gerontol A Biol Sci Med Sci 60A: 847-851, 2005.
118. Wijnen MHWA, Coolen SAJ, Vader HL, Reijenga JC, Huf FA, and Roumen RMH. Antioxidants reduce oxidative stress in claudicants. J Surg Res 96: 183-187, 2001.
119. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 344: 793-795, 1994.
120. Yudkin JS, Kumari M, Humphries SE, and Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148: 209-214, 2000.